However, the role of inherited genetic variation in Ph-like ALL pathogenesis remains unknown. In a genome-wide association study (GWAS) of 511 ALL cases and 6,661 non-ALL controls, we identified a susceptibility locus for Ph-like ALL (GATA3, rs3824662; P = 2.17 × 10 −14 , odds ratio (OR) = 3.85 for Ph-like ALL versus non-ALL; P = 1.05 × 10 −8 , OR = 3.25 for Ph-like ALL versus non-Ph-like ALL), with independent validation. The rs3824662 risk allele was associated with somatic lesions underlying Ph-like ALL (CRLF2 rearrangement, JAK gene mutation and IKZF1 deletion) and with variation in GATA3 expression. Finally, genotype at the GATA3 SNP was also associated with early treatment response and risk of ALL relapse. Our results provide insights into interactions between inherited and somatic variants and their role in ALL pathogenesis and prognosis.
variations during leukemogenesis. Similarly, in myeloproliferative neoplasms, germline variation at the JAK2 locus was linked to somatic JAK2 V617F mutation [18] [19] [20] . Together, these observations indicate that both germline and somatic genetic variations have critical roles in tumor pathogenesis.
We conducted a GWAS of Ph-like ALL to identify germline genetic variants influencing susceptibility to this ALL subtype and to evaluate the association of these variants with the somatic lesions underlying Ph-like ALL and with risk of relapse.
In the discovery GWAS, we compared genotype frequency at 718,890 SNPs in 75 children with Ph-like ALL from the Children's Oncology Group (COG) AALL0232 cohort and 6,661 non-ALL controls ( Supplementary Fig. 1 ). After adjusting for genetic ancestry, two SNPs at 10p14 within the GATA3 gene reached genome-wide significance: rs3824662 (P = 2.17 × 10 −14 , OR = 3.85 (95% CI = 2.71-5.47)) and rs3781093 (P = 4.94 × 10 −12 , OR = 3.45 (95% CI = 2.42-4.93); Fig. 1 and Table 1 ). These two SNPs were in strong linkage disequilibrium (LD; r 2 = 0.94, D′ = 1 in the HapMap CEU reference (Utah residents of Northern and Western European ancestry); Supplementary Fig. 2 ), representing a single susceptibility locus. The A allele at rs3824662 and the C allele at rs3781093 were over-represented in Ph-like ALL, conferring increased disease risk across different ancestry groups ( Table 1 and Supplementary Fig. 3) . We next performed a second GWAS comparing children in the COG AALL0232 cohort who had the Ph-like expression profile (n = 75) with those who did not have the Ph-like profile ('non-Ph-like'; n = 436). After adjusting for genetic ancestry, the same GATA3 SNPs, rs3824662 and rs3781093, exhibited the strongest association (P = 1.05 × 10 −8 , OR = 3.25 (95% CI = 2.16-4.89) and P = 2.62 × 10 −7 , OR = 2.89 (95% CI = 1.92-4.34), respectively; Table 1 and Supplementary Figs. 3 and 4) . Imputation of genotypes at 37,493 additional SNPs at this locus (chromosome 10: 60,523-10,060,447) did not identify any variants with a stronger association with Ph-like ALL than the original GWAS hits (Supplementary Fig. 5 ).
To validate the association of GATA3 SNPs with Ph-like ALL, we genotyped rs3824662 and rs3781093 in 171 children with B-ALL enrolled in the COG P9906 study and in an independent sample of 5,755 non-ALL controls. In this replication analysis, risk alleles at both GATA3 SNPs were consistently over-represented in Ph-like ALL cases (n = 32) compared to non-ALL controls (rs3824662: P = 3.69 × 10 −5 , OR = 3.14 (95% CI = 1.18-5.44); rs3781093: P = 0.0001, OR = 2.95 (95% CI = 1.68-5.16)) or compared to non-Ph-like ALL cases (n = 139) (rs3824662: P = 0.01, OR = 2.16 (95% CI = 1.18-3.97); rs3781093: P = 0.004, OR = 2.55 (95% CI = 1.33-4.88)) ( Table 1) .
To explore the functions of these germline GATA3 variants, we first examined the relationship between rs3824662 SNP genotype and GATA3 mRNA expression. In lymphoblastoid cell lines, the rs3824662[A] allele was associated with significantly higher GATA3 mRNA levels (HapMap YRI (Yoruba from Ibadan, Nigeria) reference: n = 56, P = 0.034; Fig. 2a and CEU and MEX (Mexican ancestry in Los Angeles, California) references: Supplementary Fig. 6 ). Consistently, the A allele was also associated with higher levels of DNase I hypersensitivity at this locus (HapMap YRI reference: n = 67, P = 9.5 × 10 −8 ; Fig. 2b ), indicating that this allele influences local chromatin accessibility and transcriptional activity. Association of germline GATA3 SNP genotype with GATA3 expression was confirmed in ALL blasts in both the COG AALL0232 and COG P9906 cohorts (n = 511, P = 9.2 × 10 −8 and n = 173, P = 3.6 × 10 −6 , respectively; Supplementary  Fig. 7) . Interestingly, ectopic overexpression of GATA3 in ALL cell lines consistently led to global changes in gene expression patterns, with highly significant enrichment of genes within the Ph-like ALL expression signature (UOCB1 cell line, P = 0.0004; Nalm6 cell line, P = 0.001; Supplementary Fig. 8 ).
Recurrent genomic lesions targeting lymphoid development, cytokine receptor and tyrosine kinase signaling are a hallmark of Ph-like ALL. In both COG AALL0232 and COG P9906, the GATA3 SNP rs3824662 was associated with CRLF2 lesion, JAK gene mutation and IKZF1 deletion, and these associations were also validated in a third cohort of 781 children enrolled in the COG P9905 protocol ( Table 2 ). The A risk allele at rs3824662 was further enriched in cases with multiple Ph-like ALL-related somatic lesions. In COG AALL0232, the frequency of the rs3824662[A] allele was highest in ALL cases with simultaneous CRLF2 lesion, JAK gene mutation and IKZF1 deletion (73%), next highest in cases with one or two of these lesions (40%) and lowest in cases without l e t t e r s npg l e t t e r s any of the three lesions (29%) (P = 6.09 × 10 −5 ; Fig. 3 ). This correlation was also validated in the COG P9906 cohort (P = 0.0005) and in the COG P9905 cohort (P = 7.6 × 10 −5 ; Fig. 3 ). Within Ph-like ALL, there was a trend toward the rs3824662[A] allele being over-represented in cases with CRLF2 lesions (P = 0.05; Supplementary Fig. 9 ). However, the association of rs3824662 with a Ph-like phenotype remained significant within ALL cases that were negative for CRLF2 alterations (P = 8.8 × 10 −5 ; Supplementary Fig. 9 ), JAK gene mutation (P = 2.1 × 10 −5 ) or IKZF1 deletion (P = 0.001) and in a multivariate model after adjusting for all three lesions (P = 0.001).
Given the poor prognosis of Ph-like ALL, we next examined the relationship between GATA3 SNP genotype and ALL relapse. In the COG P9906 cohort, the GATA3 allele associated with Ph-like ALL was also associated with higher risk of relapse after adjusting for genetic ancestry (rs3824662, n = 215, P = 0.002; Fig. 4a ). Whereas rs3824662 was strongly related to early treatment response (minimal residual disease (MRD) at the end of induction therapy, n = 193, P = 9.8 × 10 −5 ; Fig. 4b) , it remained prognostic even in individuals who were MRD negative (n = 132, P = 0.028). To further define the prognostic value of the GATA3 SNP, we tested the association of rs3824662 with relapse in the COG P9905 protocol. In this cohort, genotype at rs3824662 was significantly associated with relapse, with each copy of the A allele associated with a 1.43-fold increase (95% CI = 1.10-1.86) in the risk of disease recurrence (n = 781, P = 0.007; Fig. 4c ). The A allele at rs3824662 was also associated with a higher MRD level at the end of induction therapy (n = 710, P = 0.039; Fig. 4d) , and there was a trend for it to be linked to higher relapse risk in individuals negative for MRD in the COG P9905 cohort (n = 566, P = 0.094).
Although association of rs3824662 with Ph-like ALL was consistent across different ancestry groups (Supplementary Fig. 3 ), risk allele frequency varied substantially among individuals of different ancestry. In worldwide populations, the rs3824662 risk allele (associated with Ph-like ALL and relapse) was markedly more common in Guatemalans with high Native American genetic ancestry and US Hispanics than in individuals of European descent (allele frequency of 52%, 40% and 14%, respectively; Supplementary Fig.10 ), consistent with ancestry-related disparities in ALL treatment outcomes 21 .
The majority of children with ALL can be cured with individualized combination chemotherapy, and treatment outcome continues to improve as new molecular prognostic markers are incorporated to achieve more precise risk classification 2 . Until recently, little was known about why a child develops a specific subtype of ALL in the first place and whether inherited genetic variations that predispose to a particular subtype also influence prognosis 12, 14, 16 . Therefore, the goal of this GWAS was to discover the genetic basis of susceptibility to Ph-like ALL and to improve understanding of the biology of this important high-risk subtype of ALL. The discovery of GATA3 variants that are associated with Ph-like ALL and related genomic lesions points to potential new mechanisms of ALL etiology and also to a previously unrecognized function of GATA3 in leukemogenesis. The GATA3 protein belongs to a group of transcription factors characterized by two highly conserved zinc fingers that mediate binding to the (A/G)GATA(A/G) sequence and protein-protein interactions 22 . Stage-specific transcription of GATA3 has been extensively characterized during T cell development and differentiation 23 . GATA3 is critical for the generation of early T-lineage progenitor cells 24 , and somatic loss-of-function mutations in GATA3 are enriched in early T cell precursor ALL 25 . Inherited genetic variation in GATA3 has also been associated with susceptibility to Hodgkin lymphoma 26 , although the corresponding variants are not related to rs3824662 or rs3781093 (r 2 < 0.1 in the HapMap CEU reference). Other members of the GATA family are critical for different stages of hematopoietic development, and germline or somatic mutations in these genes can lead to a variety of hematologic disorders 27, 28 .
In strong LD in European, Hispanic and Asian populations (r 2 The risk allele (A) for the GATA3 SNP rs3824662 was associated with higher GATA3 mRNA levels in 56 unrelated lymphoblastoid cell lines from the HapMap YRI population (a) and was associated with increased DNase I hypersensitivity (higher transcriptional activity) in 67 unrelated YRI HapMap cell lines. Information on GATA3 expression and DNase I hypersensitivity at this locus were obtained from previously published data sets 30, 31 . Association of rs3824662 genotype (x axis) with GATA3 mRNA levels or DNase I hypersensitivity (y axis) was evaluated using a linear regression model, adjusting for genetic ancestry as appropriate. The number of cell lines analyzed per genotype is shown below each plot. AU, arbitrary units. Each box includes data between the 25th and 75th percentiles, with the horizontal line indicating the median. Whiskers indicate the maximal and minimal observations that are within 1.5 times the length of the box. RAF, risk allele frequency (allele A at rs3824662); OR, odds ratio; CI, confidence interval. Association of SNP genotype with CRLF2 genomic lesions (either IGH-CRLF2 or P2RY8-CRLF2), JAK gene mutation (JAK1, JAK2 or JAK3) or IKZF1 deletion was evaluated by comparing allele frequencies in ALL cases with and without the specific lesion or mutation after adjusting for genetic ancestry.
a P values were estimated by logistic regression test. b OR values represents the increase in the likelihood of CRLF2, JAK gene or IKZF1 somatic lesion or mutation for each copy of the A allele compared with subjects who do not carry the A allele at rs3824662. npg l e t t e r s respectively), rs3824662 and rs3781093 both achieved genome-wide significance in the discovery GWAS, with similar association with Ph-like ALL (Supplementary Figs. 2, 3 and 11) . However, rs3781093 became non-significant in multivariate analysis conditioning on rs3824662 (Supplementary Table 1 ). In African subjects in whom these two SNPs are poorly linked (r 2 = 0.006 in the HapMap YRI reference), the A allele at rs3824662 remained over-represented in Ph-like ALL, whereas rs3781093 no longer showed any evidence of association with Ph-like ALL (Supplementary Fig. 11 ). Also, rs3781093 was not associated with GATA3 expression or with local DNase I hypersensitivity in HapMap YRI samples, whereas consistent evidence points to rs3824662 as a potential expression quantitative trait locus across ancestry groups in HapMap populations (Supplementary Figs. 6  and 12 ). In fact, rs3842662 was the top SNP influencing DNase I hypersensitivity at this locus in the YRI population ( Supplementary  Fig. 12 ). Further examination of Encyclopedia of DNA Elements (ENCODE) data suggested possible enhancer activities within the region encompassing rs3824662 in lymphoblastoid cell lines on the basis of histone methylation marks and PU.1 and p300 binding (Supplementary Fig. 13 ). Although functional studies are warranted to determine the exact causal variant(s) at this locus and the molecular mechanisms by which GATA3 variants influence Ph-like ALL leukemogenesis, these lines of evidence consistently point to rs3824662 as a potentially functional variation with possibly direct contribution to the GWAS signal.
The GATA3 allele associated with Ph-like ALL was also associated with increased risk of relapse in the COG P9906 cohort, and this association was validated in the COG P9905 cohort (Fig. 4) . However, in the COG P9906 cohort, the GATA3 SNP was not prognostic after adjusting for the Ph-like phenotype, arguing that the association with relapse might be largely driven by the relationship of the GATA3 allele with Ph-like ALL. GATA3 SNP genotype was also related to CRLF2 rearrangement, JAK gene mutation and IKZF1 deletion but remained associated with Ph-like ALL after adjusting for these genomic lesions. Furthermore, we attempted to build a classification model for Ph-like ALL based on GATA3 germline SNPs, somatic lesions in CRLF2, JAK and IKZF1, and genetic ancestry in 682 cases in COG AALL0232 and COG P9906, using classification and regression tree methods (CART 29 ). In this analysis (Supplementary Fig. 14) , CRLF2, IKZF1, rs3824662 and Native American genetic ancestry were independent predictors of Ph-like ALL, and rs3824662 was associated with a Ph-like phenotype, regardless of CRLF2 status. Interestingly, Native American genetic ancestry remained a significant predictor after stratifying on the GATA3 SNP, indicating the presence of additional ancestry-related germline variants that are associated with Ph-like ALL. There was also significant over-representation of the rs3824662 risk alleles in nonPh-like ALL cases compared with non-ALL controls (P = 0.0008 and 0.00035 in the discovery GWAS and replication cohorts, respectively), suggesting effects of this variant on ALL susceptibility in general.
In conclusion, our genome-wide germline SNP analysis identified genetic variants in the GATA3 gene that influence susceptibility to Ph-like ALL and risk of relapse. These findings highlight the intricate interactions between inherited and somatic variants and their key role in the pathogenesis and prognosis of cancer in general. . Study sponsors were not directly involved in the design of the study, the collection, analysis and interpretation of data, the writing of the manuscript or the decision to submit the manuscript. Detailed acknowledgments for the dbGaP data sets are provided in the Supplementary Note. 
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Subjects. The ALL cases investigated comprised children with newly diagnosed B-precursor ALL who were treated on the Children's Oncology Group (COG) P9905 (ClinicalTrials.gov NCT00005596) 32 , P9906 (NCT00005603) 10 and AALL0232 (NCT00075725) trials 7 . Subjects were chosen on the basis of the availability of germline DNA, genotyping quality and the availability of phenotypes, as described in the text and in Supplementary Figures 15-17 and Supplementary Table 2 . Germline genomic DNA was extracted from peripheral blood or bone marrow samples obtained during clinical remission. In the discovery GWAS, 6,661 unrelated subjects from the Multi-Ethnic Study of Atherosclerosis (MESA) study (dbGaP phs000209.v11.p3) were considered as non-ALL control subjects because the prevalence of adult survivors of childhood ALL is less than 1 in 10,000 in the United States 14 . For the replication analyses, we obtained SNP genotype data for 5,755 unrelated controls: 3,647 European Americans from the Genetic Association Informative Network schizophrenia cohort (dbGAP phs000021.v3.p2) and GAIN bipolar cohort (phs000017.v3.p1) 33, 34 , 1,228 African Americans from the AIDS Linked to Intravenous Experience cohort (ALIVE) 35 and 880 Hispanic Americans from the Genetics of Asthma in Latino Americans study (GALA) 36 . Sixty-five unrelated Guatemalan subjects were selected to represent Native Americans, including 25 subjects with a self-reported indigenous background (Kiche, Mam, Chol and Qanjobal) and 40 subjects identified as mestizo (Hispanic).
Clinical trials were approved by local institutional review boards (IRBs), and informed consent for trial enrollment and banking of specimens for future research was obtained from parents, guardians or patients, as appropriate. This study was approved by the St. Jude Children's Research Hospital IRB, and research involving Guatemalan subjects was approved by the Bioethic Committee at Facultad de Medicina, Universidad Francisco Marroquin.
Genotyping and quality control. Genome-wide SNP genotyping was performed using the Affymetrix Human SNP Array 6.0 for the COG AALL0232 and COG P9905 cohorts and for all non-ALL control subjects (dbGaP MESA, ALIVE, GAIN and GALA). Genotype calls (coded as 0, 1 and 2 for AA, AB and BB genotypes, respectively) were determined by the Birdseed (Affymetrix SNP 6.0) algorithm 37 . Samples for which genotypes were ascertained for less than 95% of SNPs on the array were deemed to have failed and were excluded from the analyses. Genotyping of the GATA3 SNPs in the COG P9906 cohort and Guatemalan subjects was performed by Sanger sequencing (primers sequences are given in Supplementary Table 3) . Genome-wide SNP genotype data have been deposited in the dbGaP database maintained by the US National Institutes of Health (dbGaP phs000638.v1.p1).
Before performing GWAS, SNPs were subjected to a series of quality control steps (Supplementary Fig. 1 ). First, we filtered SNPs on the basis of minor allele frequency (MAF) and SNP call rate: for SNPs with MAF of 1-3%, we excluded those with call rate of <99%; for SNPs with MAF of 3-5%, we excluded those with call rate of <98%; and for SNPs with MAF of >5%, we excluded those with call rate of <95%. An additional filtering step was applied in the GWAS involving non-ALL controls: we removed SNPs for which genotype frequencies differed significantly among control groups (dbGaP MESA versus HapMap unrelated CEU or dbGaP MESA versus the GAIN bipolar cohort (dbGaP phs000017.v3.p1) 33 ; P < 1 × 10 −6 by χ 2 test with the comparison restricted to European Americans).
Theta (allele signal intensity) plots were constructed using Affymetrix Genotyping Console for rs3824662 and rs3781093 and were manually examined to ensure the quality of genotype calling (Supplementary Fig. 18 ). We also genotyped these two SNPs in 71 randomly selected samples for which Affymetrix 6.0 SNP array data were available and observed 99% concordance in genotype between the orthogonal methods.
Genetic ancestry and population structure. Genetic ancestry was determined using STRUCTURE (version 2.2.3) 38 on the basis of genotypes at 30,000 SNPs randomly selected from the Affymetrix SNP arrays. HapMap samples from the CEU (n = 60), YRI (n = 60) and CHB and JPT (n = 90) panels and Native American references 39 (n = 105) were used to represent European, African, Asian and Native American ancestry groups, respectively. We assumed that the proportions for these four ancestry groups summed to 100% in each genotyped individual. European Americans, African Americans, Native Americans and Asians were defined as having >95% European genetic ancestry, >70% African ancestry, >90% Native American ancestry and >90% Asian ancestry, respectively. Hispanics were individuals for whom the proportion of Native American ancestry was >10% and was greater than the proportion of African ancestry (including genetically defined Native Americans). The rest of the subjects were grouped as 'others' .
Ph-like ALL and GWAS. Ph-like ALL was identified in the COG ALL0232 cohort and in the COG P9906 cohort on the basis of unsupervised hierarchical clustering analysis of global gene expression profiles (prediction analysis of microarrays, PAM), as described previously 7, 9, 40 . Gene expression data for COG P9906 have been deposited in the GEO database maintained by the US National Institutes of Health (GSE11877), and data for COG AALL0232 have been deposited at the National Cancer Institute caArray site (EXP-578). Although a number of clinical features (for example, leukocyte count at diagnosis) were related to Ph-like ALL 6,9 , the only unequivocal clinical diagnosis of this subtype is by gene expression profiling.
The discovery GWAS comprised 511 ALL cases enrolled on the COG AALL0232 protocol and 6,661 non-ALL controls from the dbGaP MESA data set. We performed two association tests to identify germline SNPs associated with Ph-like ALL: we compared the genotype frequency at each SNP in (i) Ph-like ALL (n = 75) versus non-ALL controls (n = 6,661) and (ii) Ph-like ALL (n = 75) versus ALL cases without the Ph-like profile (non-Ph-like ALL; n = 436). Association was evaluated with logistic regression under an additive model, with European, African and Native American genetic ancestry (continuous variables) included as covariates. Population stratification was assessed by the construction of a quantile-quantile plot, and there was only minimal inflation at the upper tail of the distribution (λ = 1.01; Supplementary Fig. 19 ), indicating minimal inflation of association P values due to population structure.
SNPs that reached association P ≤ 5 × 10 −8 in the discovery GWAS were tested in an independent replication cohort of 171 ALL cases from the COG P9906 protocol and 5,755 non-ALL controls. Association with Ph-like ALL was evaluated by logistic regression with genetic ancestries as covariates by comparing (i) Ph-like ALL (n = 32) and non-ALL controls (n = 5,755) and (ii) Ph-like ALL (n = 32) and non-Ph-like ALL (n = 139). Observed effect sizes (ORs) were in general greater in the discovery cohort than in subsequent replication (Tables 1 and 2) , implying possible inflation of the effects of these variants in the original GWAS (winner's curse). Clinical and demographic characteristics varied among cases enrolled in these COG protocols (Supplementary Table 2 ) and may have also contributed to the variation in associations of rs3824662 with Ph-like ALL and related genomic lesions.
To further characterize the association signals at the GATA3 locus, we imputed SNP genotypes for chromosome 10: 60,523-10,060,447, with data for 4,339 SNPs directly genotyped on the Affymetrix 6.0 array as input, using MaCH-Admix 2.0.185 (ref. 41) . A total of 1,902 samples (246 Africans, 181 admixed Americans, 286 Asians and 379 Europeans) from the 1000 Genomes Project (Phase I Integrated Release Version 3) were used as reference, and imputation was performed for both ALL cases (n = 511) and non-ALL controls (n = 6,661) included in the discovery GWAS. After removing monomorphic SNPs and those with poor imputation quality (r 2 < 0.7), 37,493 imputed or genotyped SNPs were included in the association analyses (Ph-like ALL versus non-ALL controls and Ph-like ALL versus non-Ph-like ALL).
Independently, the Ph-like ALL phenotype was also identified by the recognition of outliers by sampling ends (ROSE) clustering algorithm 8, 10 . We identified 49 and 19 cases as Ph-like ALL in the discovery (COG AALL0232) and replication (COG P9906) groups, respectively. Association of GATA3 SNPs and Ph-like ALL inferred by ROSE was nearly identical to what was observed with PAM-based Ph-like identification (Supplementary Fig. 20) . GATA3 SNPs rs3824662 and rs3781093 were also genotyped in 90 childhood Ph+ ALL cases. Although the risk alleles were more common in Ph+ ALL than in non-ALL controls (rs3824662: 29% versus 20%, P = 0.03; rs3781093: 31% versus 22%, P = 0.003), they were not more frequent than in Ph-negative ALL. GATA3 expression in diagnostic blasts did not differ between Ph+ ALL and non-Ph+ ALL (Supplementary Fig. 21 ).
LD at the GATA3 locus (10p14) was illustrated using Haploview software and the genotypes of unrelated HapMap CEU, MEX, YRI and CHB + JPT npg samples. LD blocks were determined on the basis of r 2 (Supplementary Figs. 2  and 11) . Regional plots were constructed by plotting the negative logarithm of the P value in the GWAS for each SNP (imputed and genotyped) in a 220-kb window at the GATA3 locus using LocusZoom 42 .
GATA3 SNPs and somatic lesions in CRLF2, IKZF1 and JAK. FISH or genomic PCR were used to identify CRLF2 rearrangements (IGH-CRLF2 or P2RY8-CRLF2), as published previously 43 . ALL cases suspected of having CRLF2 lesions on the basis of gene expression array data were first analyzed with the CRLF2 break-apart FISH assay with BAC probes flanking the CRLF2 locus. Because the centromeric BAC was deleted secondary to the P2RY8-CRLF2 fusion, all cases were evaluated for loss of the centromeric BAC and for break-apart of the CRLF2 locus (IGH-CRLF2). CRLF2 lesion status was considered positive if either IGH-CRLF2 translocation or P2RY8-CRLF2 fusion was identified.
Using a custom-designed oligonucleotide tiling array (Agilent Technologies), the IKZF1 deletion was detected in diagnostic ALL blasts as previously described 43 . Briefly, tiling probes were constructed with an average spacing of 20 bp and a probe length of 50 bp, and they included 5,000 bp 5′ and 3′ of the IKZF1 gene. Genomic Workbench software (Agilent Technologies) was used to perform data analyses.
Using genomic PCR and Sanger sequencing, we identified coding mutations in the JAK1, JAK2 and JAK3 kinases, as described previously 43 . JAK1 exons 13-15, 18 and 19, JAK2 exons 16, 20 and 21, and JAK3 exons 18 and 19 were sequenced. Sequences from tumor were compared against those for matched germline samples to determine whether sequence changes were somatic.
A detailed description of the cases tested for the Ph-like gene expression profile, CRLF2 lesion, JAK gene mutation and IKZF1 deletion is provided in Supplementary Figures 15-17 .
Associations of GATA3 SNP genotype with each somatic lesion or with cumulative somatic lesions were tested using logistic regression or ordinal regression test, respectively, with genetic ancestry as covariates. We also tested 11 germline SNPs within the JAK2 gene for association with somatic JAK2 mutation but did not observe any significant relationships, i.e., SNP genotype did not differ in ALLs with and without JAK2 mutations or in ALL with JAK2 mutations and non-ALL controls (Supplementary Table 4) .
We sought to identify predictors of Ph-like ALL using the CART algorithm as implemented in R statistical software (function rpart). We considered five factors in the model: CRLF2 genomic rearrangements, JAK gene mutation, IKZF1 deletion, genetic ancestry (Native American and European ancestry) and germline GATA3 polymorphism (rs3824662). Tree building began at the root node, which included all cases with a Ph-like ALL phenotype evaluable in the combined COG AALL0232 and COG P9906 cohort (n = 682). The CART algorithm first identified the variable (CRLF2 genomic lesion) that would split the node into the two daughter nodes that differed most in the proportion of Ph-like ALL (Supplementary Fig. 14) . This process was repeated for each daughter node and was continued recursively until it was not possible to continue, owing to the small number of samples in each daughter node. As parameters for controlling tree growth, we required the minimum number of observations in a node to be 30 before attempting a split, and we required that the split must decrease the overall lack of fit by a factor of 0.001 (cost complexity factor) before being attempted, following our previously established procedures 29 .
GATA3 SNP genotype and ALL relapse. Relapse was defined as disease recurrence in bone marrow and/or extramedullary sites. Lineage switch, second malignancy and death in remission were incorporated as competing events. Genotype-relapse association was tested in the COG P9906 and COG P9905 cohorts using Fine and Gray hazard regression 44 after adjusting for genetic ancestry and treatment arms (for example, arms A-D of COG P9905 and COG P9906). MRD was measured at the end of induction therapy (day 28) by flow cytometry and was classified as negative (<0.01%), positive (≥0.01% but <1%) or high positive (≥1%). Genotype-MRD association was evaluated using the Spearman rank test. The independent prognostic values of the GATA3 SNPs were determined by multivariate analyses of relapse after adjusting for MRD.
Functional characterization of GATA3 SNPs. Expression quantitative trait locus analysis was performed to determine the relationships between GATA3 SNP genotype and GATA3 gene expression. GATA3 expression data were obtained from previously published data sets for HapMap YRI (n = 56; GSE7851) 30, 45 and CEU (n = 96; GSE5859) 46 cell lines, and expression was quantified by RT-PCR for the MEX cell lines (n = 54; Supplementary Table 3) . GATA3 expression in diagnostic ALL blasts from cases enrolled in the COG P9906 (n = 173) 10 and COG AALL0232 (n = 511) protocols 7 was ascertained by Affymetrix U133A array, as described previously. GATA3 SNP genotypes for HapMap cell lines were obtained from the HapMap website, and genotypes in children with ALL were determined using the Affymetrix 6.0 array (COG AALL0232) or by Sanger sequencing (COG P9906). DNase I hypersensitivity analysis was performed using publicly available DNase I sequencing data in unrelated HapMap YRI cell lines (n = 67), as a measurement of local chromatin accessibility 31 . Associations of GATA3 SNP genotype with GATA3 gene expression and with local DNase I hypersensitivity were assessed by a linear regression model, adjusting for genetic ancestry as appropriate.
We also queried the ENCODE data set to further characterize the possible function of the rs3824662 variant. Focusing on lymphoblastoid cells as the relevant tissue type for ALL, we examined two major types of data: histone modification marks (histone methylation and acetylation and histone-modifying enzyme chromatin immunoprecipitation and sequencing (ChIP-seq)) and transcription regulator marks (transcription factor ChIP-seq). In the ENCODE tier 1 cell line GM12878, the region encompassing rs3824662 was identified as a weak enhancer on the basis of histone markers ('state 7' of the 15 chromatin states 47 ). Close examination of the histone modifications showed relatively strong monomethylation (H3K4me1) and dimethylation (H3K4me2) of histone H3 at lysine 4, with little enrichment of trimethylation (H3K4me3), a pattern that is indicative of a potential enhancer. Also, transcription factor ChIP-seq data in lymphoblastoid cells showed significant binding of PU.1 and p300 around rs3824662, again in support of possible enhancer activity. The Epigenome Browser was used to collate and visualize ENCODE data 48 .
To examine the relationship between GATA3 SNP genotype and the Ph-like expression signature, we evaluated the association of rs3824662 genotype with the expression of each gene within the Ph-like signature. Of 147 Ph-like ALL genes, 38 were significantly associated with rs3824662 genotype in ALL blasts in COG P9906 and COG AALL0232. The Ph-like signature was also significantly enriched in genes that were differentially expressed in children carrying and not carrying the A allele at rs3824662, as determined by Gene Set Enrichment Analysis (GSEA) in both the COG P9906 and COG AALL0232 cohorts (P < 0.001 for both cohorts; Supplementary Fig. 22 ). The association of GATA3 SNP genotype and GATA3 expression in ALL blasts was also evaluated after excluding Ph-like ALL cases in both COG AALL0232 and COG P9906 (Supplementary Fig. 23 ).
Finally, we tested the effects of GATA3 expression on global transcription patterns in ALL cell lines. UOCB1 and Nalm6 cells were obtained from W.E.E. and from the German Collection of Microorganisms and Cell Cultures, respectively. Both cell lines were recently authenticated by genome-wide SNP genotype and by copy number profiling and cytogenetics, and they were tested for mycoplasma contamination. Cells were grown at 37 °C and 5% CO 2 , in RPMI-1640 containing 10% FBS and 1% glutamine. Full-length GATA3 was cloned into the MSCV-IRES-eGFP retroviral vector and packaged in lentiviral particles. Total RNA from cells stably transduced with either empty vector or vector containing GATA3 was extracted with TRIzol reagent following GFP sorting. GATA3 overexpression was confirmed by RT-PCR (Supplementary Table 3) . Total RNA (100 ng) was first processed using the Ambion Whole-Transcript assay, and biotin-labeled cDNA was hybridized to the Affymetrix HuGene 1.0 ST v1 GeneChip, according to the manufacturer's instructions. Signals were summarized using the Robust Multi-array Algorithm (Partek Genomics Suite), and 33,297 probe sets remained after excluding probe sets with >95% absent calls. Scaled expression values for all probe sets were logarithmically transformed to stabilize variance. To test for overlap between genes involved in Ph-like ALL and those affected by GATA3 overexpression, we applied GSEA to expression array data from cells transduced with GATA3-expressing versus control vectors, using the PAM Ph-like ALL gene signature as the a priori gene set. In the UOCB1 and Nalm6 cell lines, the PAM Ph-like gene set (genes upregulated in Ph-like ALL cases compared to non-Ph-like ALL cases) yielded enrichment scores of 0.52 (P = 0.0004) and 0.43 (P = 0.001), respectively npg
